Skip to content

Other, net at other companies

Artivion logo
ArtivionAORT
-$210K-18.0%
Vericel logo
VericelVCEL
-$21K-425%
Enovis logo
EnovisENOV
-$1.4M+38.4%
Alphatec Holdings logo
Alphatec HoldingsATEC
$639K+90.2%
Solventum logo
SolventumSOLV
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: MiMedx Group’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's other, net?
MiMedx Group (MDXG) reported other, net of $0 in Q4 2025.
How has MiMedx Group's other, net changed year-over-year?
MiMedx Group's other, net increased by 100.0% year-over-year, from -$14.25K to $0.
What is the long-term trend for MiMedx Group's other, net?
Over 3 years (2022 to 2025), MiMedx Group's other, net has grown at a -100.0% compound annual growth rate (CAGR), from -$41K to $0.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.